4.8 Article

Macrophage-elicited loss of estrogen receptor-α in breast cancer cells via involvement of MAPK and c-Jun at the ESR1 genomic locus

Journal

ONCOGENE
Volume 31, Issue 14, Pages 1825-1834

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/onc.2011.370

Keywords

estrogen receptor; macrophages; MAPK; breast cancer; jun

Funding

  1. Breast Cancer Research Foundation
  2. ODS, NIH [P50 AT006268]
  3. NCCAM
  4. NCI

Ask authors/readers for more resources

Estrogen receptor-alpha (ER alpha, ESR1) is a pivotal transcriptional regulator of breast cancer physiology and is targeted by endocrine therapies. Loss of ER alpha activity or expression is an indication of endocrine resistance and is associated with increased risk of tumor recurrence and worse prognosis. In this study, we sought to investigate whether elements of the tumor microenvironment, namely macrophages, would impact on ER alpha and we found that macrophage-derived factors caused loss of ER alpha expression in breast cancer cells. Conditioned media from macrophages caused activation of several intracellular pathways in breast cancer cells of which c-Src, protein kinase c and mitogen-activated protein kinase (MAPK) were essential for loss of ER alpha expression. Moreover, a prolonged hyperactivation of MAPK was observed. The activation of this kinase cascade resulted in recruitment of extracellular signal regulated kinase 2 (ERK2) directly to chromatin at the ESR1 gene locus in a process that was dependent upon activation and recruitment of the c-Jun transcription factor. Thus, we identify a novel mechanism for loss of ER alpha expression in breast cancer cells via macrophage activation of kinase cascades in the cancer cells causing transcriptional repression of the ESR1 gene by a direct chromatin action of a c-Jun/ERK2 complex. The findings in this study support an alternative mechanism, not intrinsic to the tumor cell but derived from the crosstalk with the tumor microenvironment, that could lead to endocrine resistance and might be targeted therapeutically to prevent loss of ER alpha expression in breast tumors. Oncogene (2012) 31, 1825-1834; doi: 10.1038/onc.2011.370; published online 22 August 2011

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available